

**In the Claims:**

Please cancel claims 12-17, 33-38, 45-50, 54-68, and 70, without prejudice to inclusion of the subject matter of those claims in one or more additional patent applications.

Please amend claims 1-11, 18-32, 39-44, 51-53, and 69 and add claims 71-75 to read as set forth in the enclosed "Clean Copy of Claims, as Amended." For the Examiner's convenience, a "Marked-Up Copy of Claims, as Amended" is also enclosed, wherein text added to the claims is underlined and text deleted from the claims is ~~struck through~~. The claims are listed in the clean copy in an order that the Applicants believe would be appropriate for issue, and in the marked-up copy in numerical order.

**REMARKS**

Claims 1-11, 18-32, 39-44, 51-53, 69, and 71-75 are pending. Claims 12-17, 33-38, 45-50, 54-68, and 70 have been canceled. Claims 1-11, 18-32, 39-44, 51-53, and 69 have been amended. Claims 71-75 have been added. The amendments and additions do not include new matter, as set forth in the ensuing section. No additional claim fee is believed to be due, because 34 claims have been canceled and five dependent claims have been added.

***Support in the Specification***

Grammatical corrections were made in the specification and in the claims.

In the claims, "said" was replaced with the synonym "the." Also in the claims, the abbreviation "HPC" is used in place of "hematopoietic progenitor cell" and the abbreviation "HSC" is used in place of "hematopoietic stem cell," each abbreviation being referenced parenthetically at its first instance in the claims.

In claim 10 and on pages 4 and 14, the words "epithelial" (claim 10 and page 4) and "epithelium" (page 14) were replaced with the word "endothelial." The specification indicates on page 2, lines 9-10, that KDR is a receptor for vascular endothelial growth factor.

